The collaboration hinges on the validation of the CIZ1B assay, a laboratory-developed test rooted in over three decades of research at the University of York. BBG Advanced Therapies has already launched the independent validation process required to meet federal quality standards for the test, which has previously demonstrated 95% sensitivity for Stage I detection. By integrating this biomarker technology into its laboratory operations, the partnership aims to offer a minimally invasive diagnostic tool that complements standard low-dose CT screenings.

For Cizzle Bio, the deal marks a significant milestone in a broader, phased national strategy to establish a network of high-quality laboratory partners. CEO Bill Behnke emphasized that the move addresses the critical need for earlier intervention in regions facing high cancer burdens. BioBridge Global leadership echoed this sentiment, noting that the combination of their regulatory compliance and lab infrastructure with Cizzle Bio’s proprietary technology is designed to move life-saving diagnostics from the research phase into routine clinical practice.